Cargando…

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis

Cytomegalovirus infection during antiviral prophylaxis occurs in transplant recipients despite individualized regimens based on renal function. Fifty kidney transplant recipients were assessed between 2016 and 2019 for valganciclovir dosing, ganciclovir exposure, cytomegalovirus infection, and genot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Diana D., van Zuylen, Wendy J., Novos, Talia, Stocker, Sophie, Reuter, Stephanie E., Au, Jane, Foster, Charles S. P., Day, Richard O., Horvath, Andrea R., Endre, Zoltan, Rawlinson, William D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241781/ https://www.ncbi.nlm.nih.gov/pubmed/35658598 http://dx.doi.org/10.1128/spectrum.02684-21

Ejemplares similares

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
por: Vaziri, Siavash, et al.
Publicado: (2014)

1703. Hematologic Toxicity of Valganciclovir Prophylaxis in Solid Organ Transplant Recipients as a Function of Weight-adjusted Ganciclovir Exposure
por: Campanella, Toni A, et al.
Publicado: (2020)

Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients
por: Perrottet, Nancy, et al.
Publicado: (2010)

Treatment of unilateral zone I cytomegalovirus retinitis in acute lymphoblastic leukemia with oral valganciclovir and intravitreal ganciclovir
por: Tripathy, Koushik, et al.
Publicado: (2017)

1702. Assessing the Safety and Efficacy of Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients on Hemodialysis
por: Yee, Jason, et al.
Publicado: (2020)

Subtherapeutic Exposure of Ganciclovir in Children Despite Appropriate Dosing: A Short Communication
por: Marfil, Sjanene, et al.
Publicado: (2023)

Molecular Detection and Genotyping of Human Cytomegalovirus in Kidney Transplant Recipients under Ganciclovir Prophylaxis in Iran
por: Behnezhad, Farzane, et al.
Publicado: (2022)

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
por: Doesch, Andreas O, et al.
Publicado: (2012)

High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation
por: Rissling, Olesja, et al.
Publicado: (2018)

Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results
por: Cheng, Yu-Chun, et al.
Publicado: (2021)

Optimal Use of Ganciclovir and Valganciclovir in Transplanted Patients: How Does It Relate to the Outcome?
por: Mozaffar, Maryam, et al.
Publicado: (2018)

Valganciclovir—Ganciclovir Use and Systematic Therapeutic Drug Monitoring. An Invitation to Antiviral Stewardship
por: Galar, Alicia, et al.
Publicado: (2021)

Establishment and Evaluation of a Parametric Population Pharmacokinetic Model Repository for Ganciclovir and Valganciclovir
por: Yang, Wenyu, et al.
Publicado: (2023)

Safety of Valganciclovir 450 mg 3 Times Weekly for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients Requiring Hemodialysis
por: Ecabert, Danielle, et al.
Publicado: (2021)

Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation
por: Hashim, Faris, et al.
Publicado: (2014)

P1336: ANTIVIRAL EXPOSURE TO GANCICLOVIR AND VALGANCICLOVIR IS NOT ASSOCIATED WITH INCREASED INCIDENCE OF RELAPSE OR SECONDARY MALIGNANCIES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
por: Duarte, D., et al.
Publicado: (2022)

Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients
por: Khurana, Mark P, et al.
Publicado: (2019)

1420. Case Report: Ganciclovir Subtherapeutic Dosing in a Pediatric Patient on Extracorporeal Membrane Oxygenation
por: Murphy, Mark, et al.
Publicado: (2018)

The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis
por: Klimczak-Tomaniak, Dominika, et al.
Publicado: (2019)

2715. Toxicities and clinical consequences of valganciclovir prophylaxis in solid organ transplant recipients
por: Lahoud, Chloe, et al.
Publicado: (2023)

Use of letermovir‐valganciclovir combination as a step‐down treatment after foscarnet for ganciclovir‐resistant CMV infection in kidney transplant recipients
por: Rho, Elena, et al.
Publicado: (2021)

1380. Real-world Effectiveness and Complications of Valganciclovir (VGC) Prophylaxis for Kidney Transplant (KT) Recipients at High Risk for Cytomegalovirus (CMV) infection (CMV Donor (D)+/Recipient (R)-)
por: Roumpz, Caroline G, et al.
Publicado: (2021)

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
por: Patil, A Jayaprakash, et al.
Publicado: (2010)

Cytomegalovirus retinitis treated with valganciclovir in Wegener’s granulomatosis
por: Kabata, Yoshiaki, et al.
Publicado: (2012)

Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients
por: Johansson, Inger, et al.
Publicado: (2013)

Ganciclovir-Resistant Cytomegalovirus Infection in a Kidney Transplant Recipient Successfully Treated with Foscarnet and Everolimus
por: Menghi, Viola, et al.
Publicado: (2016)

Treating HIV-associated cytomegalovirus retinitis with oral valganciclovir and intra-ocular ganciclovir by primary HIV clinicians in southern Myanmar: a retrospective analysis of routinely collected data
por: Murray, Jillian, et al.
Publicado: (2020)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
por: Kim, Jong Man, et al.
Publicado: (2015)

Pediatric Dosing of Ganciclovir and Valganciclovir: How Model‐Based Simulations Can Prevent Underexposure and Potential Treatment Failure
por: Jorga, Karin, et al.
Publicado: (2018)

1597. Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus (CMV) Infection and Disease in Solid Organ Transplant (SOT) Recipients
por: Khurana, Mark Poulsen, et al.
Publicado: (2018)

576. Half-dose Valganciclovir Prophylaxis is Safe and Cost-effective in CMV Seropositive Renal Transplant Recipients
por: shi, yiyun, et al.
Publicado: (2020)

Ganciclovir/letermovir: Rebound Cytomegalovirus hepatitis, acquired resistance to ganciclovir and nephrotoxicity: case report
Publicado: (2020)

1571. Cost-Effectiveness Analysis of Duration of Valganciclovir Prophylaxis Among CMV Serology Mismatched (Donor+/Recipient−) Lung Transplant Recipients
por: Tomko, Heather, et al.
Publicado: (2018)

Ganciclovir-resistant cytomegalovirus infection in renal transplantation
por: Vaz, Raquel, et al.
Publicado: (2014)

Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation
por: Li, Po-Hsien, et al.
Publicado: (2021)

A double masked randomised 4-week, placebo-controlled study in the USA, Thailand and Taiwan to compare the efficacy of oral valganciclovir and topical 2% ganciclovir in the treatment of cytomegalovirus anterior uveitis: study protocol
por: Takhar, Jaskirat S, et al.
Publicado: (2019)

2646. Incidence of Myelosuppression Related to Valganciclovir Prophylaxis in Solid-Organ Transplant Recipients at High Risk of CMV Disease
por: Belga, Sara, et al.
Publicado: (2019)

Ganciclovir-resistant CMV (GCV-R CMV) Infection Leads to Poor Clinical Outcomes and Economic Burden of Ganciclovir-resistant Cytomegalovirus Infection in Lung Transplant Recipients
por: Patel, Twisha, et al.
Publicado: (2017)

Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next-Generation Sequencing
por: Lodding, Isabelle P, et al.
Publicado: (2021)

1146. Thrombocytosis in Infants with Congenital Cytomegalovirus Infection Being Treated with Valganciclovir
por: Murtagh, Kathleen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lsbik21uu3pu34c3tco2eq8dmj